Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chronic Hepatitis C Virus (HCV)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02439567
What this trial is testing

Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)

Who this might be right for
Chronic Hepatitis CCirrhosisPortal Hypertension
Hospital Universitari Vall d'Hebron Research Institute 41
Large-scale testing (Phase 3)Study completedNCT02103439
What this trial is testing

An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Who this might be right for
HepatitisHepatitis CHepatitis C/ Human Immunodeficiency Virus Coinfection
Biocad 140
Not applicableWithdrawnNCT01831037
What this trial is testing

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

Who this might be right for
Chronic Hepatitis CChronic Hepatitis B
University of Arkansas
Early research (Phase 1)UnknownNCT02126137
What this trial is testing

Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection

Who this might be right for
Chronic Hepatitis C
Pontificia Universidad Catolica de Chile 20
Testing effectiveness (Phase 2)Study completedNCT00790673
What this trial is testing

CF102 in Patients With Chronic Hepatitis C Genotype 1

Who this might be right for
Chronic Hepatitis C
Can-Fite BioPharma 32
Large-scale testing (Phase 3)Study completedNCT01667731
What this trial is testing

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Who this might be right for
Hepatitis CHuman Immunodeficiency Virus
Gilead Sciences 224
Large-scale testing (Phase 3)Study completedNCT00381953
What this trial is testing

High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

Who this might be right for
Hepatitis C
Foundation for Liver Research 33
Testing effectiveness (Phase 2)Study completedNCT01072695
What this trial is testing

Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

Who this might be right for
HCV Infection
Gilead Sciences 46
Early research (Phase 1)Study completedNCT01497327
What this trial is testing

Open-Label Hepatic Impairment Study

Who this might be right for
Hepatitis C
Gilead Sciences 24
Not applicableStudy completedNCT02628717
What this trial is testing

Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)

Who this might be right for
Chronic Hepatitis CCirrhosis
Medical University of Vienna 558
Not applicableStudy completedNCT01457755
What this trial is testing

Gilead Sustained Virologic Response (SVR) Registry

Who this might be right for
Hepatitis C, Chronic
Gilead Sciences 6,625
Not applicableUnknownNCT05376943
What this trial is testing

Possible Differences in HCC Course Depending on DAA Treatment

Who this might be right for
Carcinoma, HepatocellularHepatitis C Virus Infection, Response to Therapy ofDrug Effect+3 more
Medical University of Warsaw 100
Early research (Phase 1)Study completedNCT01211626
What this trial is testing

Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)

Who this might be right for
HCV Infection
Hoffmann-La Roche 75
Not applicableStudy completedNCT02803138
What this trial is testing

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

Who this might be right for
Chronic Hepatitis C
AbbVie 256
Large-scale testing (Phase 3)Study completedNCT02639338
What this trial is testing

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

Who this might be right for
Hepatitis C Virus Infection
Gilead Sciences 220
Early research (Phase 1)Study completedNCT01018615
What this trial is testing

Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C

Who this might be right for
Chronic Hepatitis COxidative Stress
University of North Carolina, Chapel Hill 28
Large-scale testing (Phase 3)Study completedNCT01290731
What this trial is testing

TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Who this might be right for
Hepatitis C, Chronic
Janssen Pharmaceutical K.K. 49
Large-scale testing (Phase 3)Study completedNCT02032901
What this trial is testing

Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

Who this might be right for
Hepatitis C
Bristol-Myers Squibb 173
Testing effectiveness (Phase 2)Study completedNCT02138253
What this trial is testing

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

Who this might be right for
Liver FibrosisHepatic FibrosisLiver Cirrhosis+1 more
Conatus Pharmaceuticals Inc. 64
Large-scale testing (Phase 3)Study completedNCT01979939
What this trial is testing

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Who this might be right for
Hepatitis C
Bristol-Myers Squibb 416
Next Page